

Ascendiant Capital Markets LLC serves as Sole Placement Agent on \$2,215,000 Private Placement for NovaBay Pharmaceuticals, Inc.

IRVINE, Calif., March 28, 2019 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the completion of a \$2,215,000 Private Placement for NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) of Emeryville, California.

Ascendiant served as the Sole Placement Agent on the transaction.

NovaBay intends to use the proceeds for working capital and general corporate purposes.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets. For more information, please visit www.novabay.com

About Ascendiant Capital Markets LLC

Ascendiant Capital Markets, LLC, based in Irvine, California, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendiant has led or participated in over \$1 billion in financing transactions, and the members of Ascendiant's Investment Banking Team have completed over 300 M&A transactions.

Ascendiant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendiant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 949.259.4949 or bwilhite@ascendiant.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.